Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Results of the TRANSCEND study of CAR T Cell Product JCAR017 in patients with R/R aggressive B-NHL

Jeremy Abramson • 11 Dec 2017
ASH 2017
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel
TRANSCEND-NHL-001

Dr Jeremy Abramson, MD, from the Massachusetts General Hospital, Boston, MA, gives us a detailed presentation of progress in the TRANSCEND-NHL-001 trial (NCT02631044) presented at the ASH 2017 meeting in Atlanta, GA. He covers the rationale, design, results and safety profile as well as giving us his opinion on the data.

More from Jeremy Abramson

2:52
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
Jeremy Abramson • 12 Dec 2022
2:05
Emerging treatment strategies for patients with high-risk follicular lymphoma
Jeremy Abramson • 12 Dec 2022
3:23
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
Jeremy Abramson • 12 Dec 2022
2:46
TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
Jeremy Abramson • 12 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals